Onconic Therapeutics Inc
476060
Company Profile
Business description
Onconic Therapeutics Inc is a company that researches and develops new drugs for gastrointestinal diseases and anticancers, which have large unmet medical needs. Its pipeline products are Zataprazan(OCN-101) and OCN-201.
Contact
12 Teheran-ro 26-gil
11th floor, Jeil Vision Tower
Gangnam-gu
Seoul06236
KORT: +82 234540780
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
32
Stocks News & Analysis
stocks
Hostile takeover on the cards for this ASX income opportunity
IFM lobs reasonable takeover offer.
stocks
Get ready for major US tech earnings starting tomorrow morning
Microsoft, Amazon, Alphabet, and Meta will all release quarterly earnings. Here’s what analysts are looking for.
stocks
Corning’s AI fiber boom is real, but its stock price may be getting out of hand
Corning’s optical fiber business is thriving, and the Meta deal derisks its supply buildout, but success isn’t guaranteed.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,935.00 | 14.40 | -0.16% |
| CAC 40 | 8,104.09 | 37.83 | -0.46% |
| DAX 40 | 24,018.26 | 65.27 | -0.27% |
| Dow JONES (US) | 49,141.93 | 25.86 | -0.05% |
| FTSE 100 | 10,332.79 | 11.70 | 0.11% |
| HKSE | 25,679.78 | 245.87 | -0.95% |
| NASDAQ | 24,663.80 | 223.30 | -0.90% |
| Nikkei 225 | 59,917.46 | 619.90 | -1.02% |
| NZX 50 Index | 12,728.88 | 35.52 | -0.28% |
| S&P 500 | 7,138.80 | 35.11 | -0.49% |
| S&P/ASX 200 | 8,710.70 | 10.50 | -0.12% |
| SSE Composite Index | 4,078.64 | 7.71 | -0.19% |